These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26688903)

  • 21. Prescribing practices for Betahistine.
    Phillips JS; Prinsley PR
    Br J Clin Pharmacol; 2008 Apr; 65(4):470-1. PubMed ID: 18279470
    [No Abstract]   [Full Text] [Related]  

  • 22. [The effects of betahistine on the function of equilibrium system].
    Kubiczkowa J
    Otolaryngol Pol; 1997; 51 Suppl 25():230-9. PubMed ID: 9757700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification.
    Lacour M
    J Vestib Res; 2013; 23(3):139-51. PubMed ID: 24177346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study.
    Elbaz P
    Acta Otolaryngol Suppl; 1988; 460():143-8. PubMed ID: 3074614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology].
    Gornostaeva GV; Varakin IuIa; Prokopovich ME; Alekseeva NS; Fedin PA; Chechetkin AO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):14-7. PubMed ID: 16250576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy outcomes after maternal betahistine exposure: A case series.
    Buharalioglu CK; Acar S; Erol-Coskun H; Küçüksolak G; Karadas B; Kaya-Temiz T; Kaplan YC
    Reprod Toxicol; 2018 Aug; 79():79-83. PubMed ID: 29908288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study.
    Parfenov VA; Golyk VA; Matsnev EI; Morozova SV; Melnikov OA; Antonenko LM; Sigaleva EE; Situkho MI; Asaulenko OI; Popovych VI; Zamergrad MV
    PLoS One; 2017; 12(3):e0174114. PubMed ID: 28358888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of betaserk in experimental motor disease].
    Mantsev EI; Sigaleva EE
    Vestn Otorinolaringol; 2005; (6):49-52. PubMed ID: 16353011
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rehabilitation of patients with peripheral vestibular disorders].
    Morozova SV; Zaĭtseva OV
    Vestn Otorinolaringol; 2004; (2):59-61. PubMed ID: 15139364
    [No Abstract]   [Full Text] [Related]  

  • 30. Benign paroxysmal positional vertigo (BPPV): influence of pharmacotherapy and rehabilitation therapy on patients' recovery rate and life quality.
    Maslovara S; Soldo SB; Puksec M; Balaban B; Penavic IP
    NeuroRehabilitation; 2012; 31(4):435-41. PubMed ID: 23232168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Betaserk in therapy of cochleovestibular disordes].
    Khrapko NS; Sedykh MI; As'kova LN; Tarasova NV; Velikanov AK; Baryshevskaia LA
    Vestn Otorinolaringol; 2006; (4):59-60. PubMed ID: 17152479
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current methods for diagnosis and treatment of iatrogenic ototoxicity].
    Pavlyushina EM; Morozova SV
    Vestn Otorinolaringol; 2007; (5):38-43. PubMed ID: 18175413
    [No Abstract]   [Full Text] [Related]  

  • 33. [Betaserc in symptomatic therapy of multiple sclerosis].
    Boĭko AN; Derevianko SN; Luchikhin LA; Slanova AV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(1):42-5. PubMed ID: 11842621
    [No Abstract]   [Full Text] [Related]  

  • 34. [Seven principles in the treatment of vestibular vertigo and results of the study of VIRTUOSO].
    Zamergrad MV; Parfenov VA; Matsnev EI; Morozova SV; Melnikov OA; Sigaleva EE; Antonenko LM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12):106-110. PubMed ID: 29376992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The use of betaserk in patients with cochlear-vestibular disorders].
    Kadymov MI; Poliakova TS; Vladimirova TN
    Vestn Otorinolaringol; 1998; (5):49-50. PubMed ID: 9793432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation.
    Mira E
    Int J Clin Pract; 2008 Jan; 62(1):109-14. PubMed ID: 17537195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Betaserk efficiency in cochlear and vestibular disorders in the regional surdocenter].
    Pekaskiĭ SI
    Vestn Otorinolaringol; 2001; (3):61. PubMed ID: 11510053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical use of Bethahistine mesylate].
    Satake K; Ogino H; Yamaguchi H
    Jibiinkoka; 1969 Dec; 41(12):989-92. PubMed ID: 4984188
    [No Abstract]   [Full Text] [Related]  

  • 39. [Betaserc treatment of acute disorders of cerebral circulation with vestibulo-ataxic and cochleo-vestibular syndromes].
    Berdichevskiĭ MIa; Karmirian SA; Geĭko II; Miroshnichenko VE; Parkhaeva TN; Popova VG; Timchenko LV; Filina TV; Aristova LA
    Vestn Otorinolaringol; 2002; (4):32-3. PubMed ID: 12400131
    [No Abstract]   [Full Text] [Related]  

  • 40. [Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results].
    Kantor I; Jurkiewicz D
    Pol Merkur Lekarski; 2006 Mar; 20(117):318-21. PubMed ID: 16780265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.